Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2011

Eurofins Wins Contract to Supply U.K. Research Councils with DNA Sequencing Services

  • Eurofins MWG Operon has secured a two-year contract to supply DNA sequencing services to the seven research councils in the U.K. The deal, which may be extended to three years, has been made with Research Councils U.K. Shared Services Centre, which provides centralized services to the research councils and their institutes. It builds on a five-year relationship through which Eurofins acts as the preferred supplier of synthetic DNA and RNA oligonucleotides to the research councils.  

    “This contract will allow us to demonstrate our competence and strength in genomic services beyond the provision of synthetic DNA and RNA oligonucleotides,” comments Bruno Poddevin, svp for genomic services at Eurofins. “The synergies across our service offerings allow us to optimize our client service, from ordering convenience to streamlined processes through to faster turnaround time.”

    Eurofins MWG Operon offers genomic services spanning next-generation and custom sequencing, custom DNA sequencing, oligonucleotides, siRNA, and gene synthesis.  


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »